June 28th 2016: Synthetic Biologics: Protecting the Gut Microbiome and Maintaining Human Health |eCard

SIGN-UP NOW! Click to become a The VoiceAmerica Talk Member for Free!

C. diff. Spores and More

Tuesday at 10 AM Pacific

June 28th 2016: Synthetic Biologics: Protecting the Gut Microbiome and Maintaining Human Health

Join us as we discuss the protection of the natural gut microbiome from the unintended consequences of intravenous (IV) antibiotics which are excreted into the gut is expected to protect against opportunistic enteric infections. Recent clinical data suggest that the absence or abundance of certain microbes may be directly linked to certain infections and diseases, including Clostridium difficile infection (CDI) and irritable bowel syndrome (IBS). Synthetic Biologics is developing two microbiome-focused drug candidates in Phase 2 development including, SYN-004 which is designed to protect the g

Read more

DOWNLOAD PDF

GET CODE

Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel

LISTEN LIVE

EPISODE ON DEMAND

VIEW HOST PAGE

Questions? Comments?
Call In Live! Call-In
Toll Free: 1-866-472-5792
Intl: 001-480-553-5759

Featured Guests

Dr Joseph Sliman MD

Dr. Sliman, MD, MPH, Chief Medical Officer joined Synthetic Biologics in January 2013 as the Senior Vice President, Clinical & Regulatory Affairs. Biologics in January 2013 as the Senior Vice President, Clinical & Regulatory Affairs. In this position, Dr. Sliman will be responsible for the design and implementation of all aspects of clinical development, including clinical trials, and will lead the Company’s regulatory initiatives. During his service in the United States Navy, Dr. Sliman led the U. S. Pacific Fleet disease surveillance programs, including influenza surveillance, preparedness, and prevention, as well as communicable disease and injury surveillance and prevention and healt

Read more

Dr Mark Pimentel MD, FRCP(C)

Mark Pimentel, MD, FRCPC, is Director of the GI Motility Program and Laboratory at Cedars-Sinai, Associate Professor of Medicine at CSMC and Professor of Medicine at UCLA Geffen School of Medicine in Los Angeles, CA. Dr. Pimentel completed three years of undergraduate degree with honors in microbiology and biochemistry at the University of Manitoba, Canada. This was followed by his medical degree and his BSc(Med) from the Univeristy of Manitoba Health Sciences Center in Winnipeg, Manitoba, Canada where he also completed a residency in internal medicine.

Read more

Share This Episode

Share On Facebook

Share On Twitter

Share On LinkedIn

Share this E-mail

https://www.voiceamerica.com/show/2441/c-diff-spores-and-more 29/04/2024 08:00 29/04/2024 09:00 C. diff. Spores and More https://www.voiceamerica.com/show/2441/c-diff-spores-and-more Join us as we discuss the protection of the natural gut microbiome from the unintended consequences of intravenous (IV) antibiotics which are excreted into the gut is expected to protect against opportunistic enteric infections. Recent clinical data suggest that the absence or abundance of certain microbes may be directly linked to certain infections and diseases, including Clostridium difficile infection (CDI) and irritable bowel syndrome (IBS). Synthetic Biologics is developing two microbiome-focused drug candidates in Phase 2 development including, SYN-004 which is designed to protect the gut microbiome by degrading certain IV beta-lactam antibiotics for the prevention of CDI, AAD and the emergence of antibiotic-resistant organisms, and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). VoiceAmerica | Talk Radio | Online Talk Radio studio@voiceamerica.com false DD/MM/YYYY

Add to Calendar

Email the Host

Connect with VoiceAmerica

Download our mobile apps